MEDICOVER AB Logo
SE0009778848
A2DRQV
0RPS.L

MEDICOVER AB

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Medicover misses revenue growth in Q3 and warns of a slowdown

    Medicover reports revenue growth of 12.1% (organic 12.4%) in the third quarter of 2025, below consensus expectations of 14.5% (organic 14.3%). The Healthcare Services segment grew 9.6% with strong gains in Poland and Romania; India showed a reported decline of -1.5% due to currency effects. Diagnostic Services increased by 17.8%, lab test volumes rose 17.4%, and the adjusted EBITDA margin improved to 17.2%. Acquisitions supported revenue and margins, and leverage fell to 3.2x. Management expects a slowdown from Q4 for several quarters because of more cautious consumer behaviour and the ramp-up of two new hospitals in India. » More on de.investing.com


  • Medicover increases revenue and margin in the second quarter of 2025

    Medicover recorded revenue growth of 17.1% in the second quarter of 2025 and improved its adjusted EBITDA margin to 16.9%. The main growth drivers were the Healthcare Services division and business in Poland, while new units in India and Romania continued to weigh on margins. Net debt increased slightly due to acquisitions, but management expects a relaxation in the second half of the year. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, MEDICOVER AB has already paid €0.0184 in dividends. The last payout was in May.

Financials

In the last quarter, MEDICOVER AB had revenue of €570.8M and net profit of €25.7M
(EUR) September 2026
YoY
Revenue 570.8M 4.60%
Gross profit 141.2M 0.59%
Net profit 25.7M 30.32%
EBITDA 101.9M 3.34%

Fundamentals

Metric Value
Market capitalization
€3.56B
Number of shares
151.97M
52-week high/low
€25.52 - €16.09
Dividend yield
0.08%
Dividends TTM
€0.0184
Beta
1.51
P/E ratio
39.73
PEG ratio
1.28
P/B ratio
6.60
P/S ratio
1.46

Company profile

Medicover AB (publ) provides healthcare and diagnostic services in Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company operates 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries; and 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. It serves corporate and private customers, and patients, as well as public payers. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.

Name
MEDICOVER AB
CEO
John Paul Stubbington
Headquarters Stockholm, ab
USA
Website
IPO
11/12/2020
Employees 49,000

Ticker symbols

Exchange Symbol
London Stock Exchange
0RPS.L
Sto
MCOV-B.ST
Pnk
MCVEF
Frankfurt
5M0B.F
Düsseldorf
5M0B.DU
London
0RPS.L
Stockholm
MCOV B.ST
München
5M0B.MU
🍪

Parqet  uses cookies. Learn more